Context Therapeutics Inc. (formerly NASDAQ: CNTX) was a clinical-stage biopharmaceutical company dedicated to advancing treatments for hormone-driven women's cancers, including breast, ovarian, and endometrial cancers. Their lead product candidate was Onapristone XR (ONA-XR), an oral progesterone receptor antagonist. In late 2023, following the termination of a planned merger with PDS Biotechnology, Context Therapeutics announced its intent to wind down operations, discontinue further development of its clinical programs, and explore strategic alternatives for its assets.
Served as the central hub for corporate administration, clinical development oversight, research collaborations, and strategic decision-making.
Likely located within Philadelphia's uCity Square, a hub for life sciences and technology companies, offering modern lab and office facilities.
As a clinical-stage biotech, the culture was likely mission-driven, fast-paced, and collaborative, with a strong emphasis on scientific innovation and patient impact.
The Philadelphia location provided access to a rich ecosystem of academic research institutions, talent, and potential partners in the biopharmaceutical industry.
While headquartered in the United States, Context Therapeutics's clinical trial activities for its product candidates may have involved sites and investigators internationally, typical for biopharmaceutical development. However, the company did not have a substantial physical global office infrastructure, focusing its core operations in the US prior to its wind-down.
3675 Market Street, Suite 200
Philadelphia
PA
USA
Address: N/A
N/A
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Context Therapeutics' leadership includes:
Context Therapeutics has been backed by several prominent investors over the years, including:
Following the announcement in December 2023 to wind down operations, it is anticipated that the key executive team members have transitioned out of their roles as the company ceases its primary activities. No new executive hires are expected under these circumstances.
Discover the tools Context Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats for companies like Context Therapeutics typically involved combinations of first name, last name, or initials. Given the company's wind-down, these email addresses are likely no longer active.
[first_initial][last]@contexttherapeutics.com
Format
mlehr@contexttherapeutics.com (example for former CEO Martin Lehr, likely inactive)
Example
0%
Success rate
GlobeNewswire • December 28, 2023
Context Therapeutics Inc. announced the mutual termination of its previously announced merger agreement with PDS Biotechnology Corporation. Concurrently, Context’s Board of Directors authorized a plan to wind down the Company’s operations, discontinue further development of its clinical-stage asset ONA-XR and other preclinical programs, and pursue the sale or disposition of its assets. The Company also intends to voluntarily delist its common stock from The Nasdaq Capital Market....more
GlobeNewswire • July 24, 2023
Context Therapeutics Inc. and PDS Biotechnology Corporation (Nasdaq: PDSB) announced they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The proposed merger aimed to create a company focused on advancing PDS Biotech's pipeline of clinical-stage immunotherapies and infectious disease vaccines....more
GlobeNewswire • October 5, 2022
Context Therapeutics Inc. announced preliminary clinical data from the ongoing Phase 2 OATH trial evaluating onapristone extended-release (ONA-XR) in combination with anastrozole for the treatment of estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) in postmenopausal women who have progressed on prior CDK4/6 inhibitor therapy....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Context Therapeutics, are just a search away.